Lesinurad (Zurampic®) for the treatment of hyperuricaemia in gout patients
The National Health Care Institute carried out an assessment whether lesinurad (Zurampic®) is interchangeable with any product that is already included in the Medicine Reimbursement System (GVS).
Registration
Lesinurad (Zurampic®), in combination with a xanthine oxidase inhibitor (allopurinol or febuxostat), is indicated in adults for the supplementary treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
Advice on inclusion in the GVS
Advised by the Scientific Advisory Board (WAR), the National Health Care Institute concludes that lesinurad, as supplementary treatment for adult patients with gout, has a lower therapeutic value due to insufficient data on its effectiveness on patients who have received an adequate dose of xanthine oxidase inhibitor in accordance with the Dutch guidelines.
Based on the above considerations, the National Health Care Institute advises the Minister not to include lesinurad in the GVS.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.